BACARDI
1.2.2021 13:02:13 CET | Business Wire | Press release
Bacardi Limited, the world's largest privately-held spirits company, has its eye on the future. It just released the Bacardi Cocktail Trends Report , the company's second annual edition, revealing how recent cultural shifts have reshaped the beverage industry. Created in collaboration with The Future Laboratory (TFL), a London-based consultancy, the report predicts the changes that will happen in cocktail consumption in 2021. It also relates insights collected from the global network of Bacardi ambassadors, as well as bartenders and other industry experts.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210201005196/en/
"The pandemic has shifted mindsets and accelerated emerging trends, and the Bacardi Cocktail Trends Report is a window to these changes," says Brenda Fiala, Global Vice President, Strategic Insights and Analytics for Bacardi.
"These insights help us navigate the consumer landscape and set the course for future growth, as we enter a new year in which adults of legal drinking age are looking forward to reestablishing connection, creating new rituals, and toasting to simple moments of celebration with loved ones."
-
Domestic hedonism.
The pandemic has transformed our homes into the focal point of our social lives. In the UK, one in five people are hosting virtual gatherings; 40% of U.S. consumers are interested in make-at-home cocktail kits and to-go cocktails (Nielsen CGA).
Prior to lockdowns, only 1% of spirits sales were online as people weren’t really aware of shopping of bottles or cocktails via their browsers. Within weeks of lockdowns, consumers discovered they can buy spirits online and have them delivered right to their door, leading to exponential growth of online spirits sales. A new culture of convenience, enabled by the meteoric rise of e-comm, is on the rise.
Drizly, an alcohol e-commerce platform, grew by 350% in 2020, according to IWSR. An appetite for convenience, and a new abundance of caution, have together sparked a 131% rise in ready-to-drink (RTD) canned cocktails in the U.S. (Nielsen CGA).
As this category flourishes further this year, expect to see some new players in the game.
-
Gustatory thrill-seeking.
A longing for nostalgic comforts, combined with a desire for escapism, have led many drinkers to craft their own twists on classic cocktails and dabble in edgy flavoring. Many more people are now keen to venture beyond their cocktail comfort zone, and are exploring novel, intense flavors, infusing their drinks with spicy, smoky, super-sweet, and bitter tastes.
The Italian aperitivo is being embraced across the globe, spiking interest in bitters in particular. As consumers thirst for a familiar reprieve from lockdown life, classic cocktails are also growing in popularity, as are pursuits of fun twists on these time-honored staples.
More people are pushing the boundaries of experimentation with cocktails like the chili whisky sour and turmeric-infused gin and ginger cocktails, suggesting the emergence of gustatory thrill-seeking.
“The classics are back – but with a futuristic twist,” says Martin Raymond, co-founder of The Future Laboratory. He further predicts that, “At home, we’ve learned to make these drinks. But once bars are up and running again, we’ll be expecting our favorite bartenders and places to match, confound and challenge us with the future faced fusions and variation builds and tastes they’ve been perfecting during lockdown – super-charged bitters, volatile sweets when we expect gentle sours, even hyper-local elixirs that distil the best weeds, mosses, and lichens with the exactness of a chemist. If yesterday’s bartender was about skill and mixology, tomorrow’s one is a about alchemy and disruption.”
-
Experimental aficionados.
Post-lockdown, having experimented with homemade cocktails, consumers will be armed with a newfound knowledge of spirits and cocktails. This shift will fuel a reinvention of bars, led by an informed appreciation for bartenders' skills.
According to Bacardi, 20% of customers are now keen to explore drinks that weren't on their radar pre-lockdown, including premium versions of their favorite spirits or of others they haven't sampled before. As a result, we'll see more elevated, to-go options, as well as premium batched cocktails.
In North America, the best premiumization opportunities are in tequila (60%), dark rum (32%), and mezcal (29%). In Europe, gin is booming, and it is the top trending spirit globally (51%), based on insights gleaned from the Bacardi Global Brand Ambassador Survey.
-
Sustainability savvy.
The pandemic has not derailed the focus on sustainability and transparency. These issues remain at the forefront of the minds of spirits’ consumers, with nearly 70% of them in the U.S. and Canada agreeing that it's important for a brand to be sustainable or eco-friendly (IBM, National Retail Association Federation).
This desire for more environmentally conscious consumption has also entered into bars and restaurants. 58% of Bacardi brand ambassadors in North America say they have noticed an increase in bartenders’ interest in zero-waste ingredients.
-
Moderation mediated by mindfulness.
As people seek mindful options, low-ABV and non-alcoholic cocktails provide an alternative, and this market is continuing to grow at a fast pace. While Western Europe is leading the NoLo trend, globally, 22% of consumers are drinking less in general, and 55% of mindful drinkers are consuming low-ABV drinks.
Bars and restaurants are starting to take note of this shift. Many have adopted hybrid menus that offer drinks in both alcoholic and non-alcoholic versions, and many more likely will this year.
Download the complete Bacardi Cocktail Trends Report 2021 and Infographic .
About Bacardi Limited
Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded more than 158 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 7,000, operates production facilities in 11 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit http://www.bacardilimited.com or follow us on Twitter , LinkedIn or Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005196/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
